Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
1. Mesoblast plans to issue up to $50 million convertible notes. 2. Funding aims to reduce existing debt and support working capital. 3. Convertible notes have a 5% coupon rate over five years. 4. Investors may convert notes to shares at a premium price. 5. Company's lead product Ryoncil is crucial for inflammatory diseases.